Loading...

Brilliant Violet 510™ anti-mouse CD45 Antibody

Pricing & Availability
Clone
30-F11 (See other available formats)
Regulatory Status
RUO
Other Names
T200, Ly-5, LCA
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
30F11_BV510_CD45_Antibody_FC_083112
C57BL/6 mouse splenocytes were stained with CD45 (clone 30-F11) Brilliant Violet 510™.
  • 30F11_BV510_CD45_Antibody_FC_083112
    C57BL/6 mouse splenocytes were stained with CD45 (clone 30-F11) Brilliant Violet 510™.
Compare all formats See Brilliant Violet 510™ spectral data
Cat # Size Price Quantity Check Availability Save
103137 125 µL 146€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
103138 50 µg 194€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD45 is a 180-240 kD glycoprotein also known as the leukocyte common antigen (LCA), T200, or Ly-5. It is a member of the protein tyrosine phosphatase (PTP) family, expressed on all hematopoietic cells except mature erythrocytes and platelets. There are different isoforms of CD45 that arise from variable splicing of exons 4, 5, and 6, which encode A, B, and C determinants, respectively. CD45 plays a key role in TCR and BCR signal transduction. These isoforms are very specific to the activation and maturation state of the cell as well as cell type. The primary ligands for CD45 are galectin-1, CD2, CD3, CD4, TCR, CD22, and Thy-1.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 510™ under optimal conditions.
Concentration
µg sizes: 0.2 mg/mL
µL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. For immunofluorescent staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 510™ excites at 405 nm and emits at 510 nm. The bandpass filter 510/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 510™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Clone 30-F11 reacts with all isoforms and both CD45.1 and CD45.2 alloantigens of CD45.

Additional reported applications (for relevant formats) include: immunoprecipitation3, complement-dependent cytotoxicity1,5, immunohistochemistry (acetone-fixed frozen sections, zinc-fixed paraffin-embedded sections and formalin-fixed paraffin-embedded sections)4,6, Western blotting7, and spatial biology (IBEX)10,11. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 103163 and 103164).

Application References

(PubMed link indicates BioLegend citation)
  1. Podd BS, et al. 2006. J. Immunol. 176:6532. (FC, CMCD) PubMed
  2. Haynes NM, et al. 2007. J. Immunol. 179:5099. (FC)
  3. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IP)
  4. Simon DI, et al. 2000. J. Clin. Invest. 105:293. (IHC)
  5. Seaman WE. 1983. J. Immunol. 130:1713. (CMCD)
  6. Cornet A, et al. 2001. P. Natl. Acad. Sci. USA 98:13306. (IHC)
  7. Tsuboi S and Fukuda M. 1998. J. Biol. Chem. 273:30680. (WB) PubMed
  8. Liu F, et al. 2012. Blood. 119:3295. PubMed
  9. Pelletier AN, et al. 2012. J. Immunol. 188:5561. PubMed
  10. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  11. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Kalavska K, et al. 2022. Life (Basel). 12:. PubMed
  2. Michalek S, et al. 2022. EMBO Rep. 23:e54195. PubMed
  3. Jowett GM, et al. 2022. Cell Rep. 40:111281. PubMed
  4. Sugitani N, et al. 2022. Cell Rep. 40:111371. PubMed
  5. Olofsen PA, et al. 2022. Cells. 11:. PubMed
  6. Matter AL, et al. 2022. J Immunol. 209:1880. PubMed
  7. Chen X, et al. 2023. Adv Mater. 35:e2210440. PubMed
  8. Zhao Q, et al. 2023. Signal Transduct Target Ther. 8:40. PubMed
  9. Chen R, et al. 2023. Acta Pharm Sin B. 13:128. PubMed
  10. Li X, et al. 2023. J Clin Invest. 133:. PubMed
  11. Veras FP, et al. 2023. Respir Res. 24:66. PubMed
  12. Vaillancourt M, et al. 2023. PLoS Pathog. 19:e1010942. PubMed
  13. Solier S, et al. 2023. Nature. 617:386. PubMed
  14. Seclì L, et al. 2023. J Immunother Cancer. 11:. PubMed
  15. Gao Y, et al. 2023. iScience. 26:106729. PubMed
  16. Pitzer Mutchler A, et al. 2023. Front Physiol. 14:1167904. PubMed
  17. Distel JS, et al. 2023. PLoS Pathog. 19:e1011173. PubMed
  18. Liu Y, et al. 2021. Cell Metabolism. 33(6):1221-1233.e11. PubMed
  19. Petrova T, et al. 2020. Sci Rep. 10:3479. PubMed
  20. Rosina M, et al. 2022. Cell Metab. 34:533. PubMed
  21. Leslie J, et al. 2021. Sci Rep. 11:1415. PubMed
  22. Denny L, et al. 2021. Clin Transl Immunology. 10:e1234. PubMed
  23. Li DD, et al. 2022. J Cell Mol Med. 26:2438. PubMed
  24. Agarwalla P, et al. 2022. Nat Biotechnol. 40:1250. PubMed
  25. Yang Z, et al. 2022. Cancer Discov. 12:1942. PubMed
  26. Garnier L, et al. 2022. Sci Adv. 8:eabl5162. PubMed
  27. Liang Y, et al. 2022. Theranostics. 12:7729. PubMed
  28. Briukhovetska D, et al. 2023. Immunity. 56:143. PubMed
  29. Caslin HL, et al. 2023. Front Immunol. 13:984859. PubMed
  30. Wang L, et al. 2023. Oxid Med Cell Longev. 2023:6480848. PubMed
  31. Abu Hejleh AP, et al. 2023. Int J Tryptophan Res. 16:11786469231153111. PubMed
  32. Jiang L, et al. 2021. Nano Today. 36:. PubMed
  33. Allen SD, et al. 2021. Biomaterials. 269:120635. PubMed
  34. Dube CT, et al. 2022. Epigenetics. 17:444. PubMed
  35. Xu J, et al. 2022. Dev Cell. 57:839. PubMed
  36. Hentzschel F, et al. 2022. Sci Adv. 8:eabm7348. PubMed
  37. Mackel JJ, et al. 2022. Front Cell Infect Microbiol. 12:974175. PubMed
  38. Cornax I, et al. 2021. Microorganisms. 9:00. PubMed
  39. Benitez AA, et al. 2020. Commun Biol. 0.371527778. PubMed
  40. Gawish R, et al. 2022. Elife. 11:. PubMed
  41. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  42. Boal-Carvalho I, et al. 2020. EMBO Rep. 21:e50421. PubMed
  43. Afolabi LO, et al. 2021. Front Immunol. 12:701671. PubMed
  44. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  45. Li JY, et al. 2020. J Clin Invest. 130:1767. PubMed
  46. Dong L, et al. 2021. Cancer Cell. . PubMed
  47. Pan XX, et al. 2021. Front Cell Dev Biol. 637424:9. PubMed
  48. Scott CL et al. 2018. Immunity. 49(2):312-325 . PubMed
  49. Lancaster JN, et al. 2019. Nat Commun. 10:2220. PubMed
  50. Zhang K, et al. 2018. PLoS Pathog. 14:e1006925. PubMed
  51. Li Y, et al. 2021. Basic Res Cardiol. 116:30. PubMed
  52. Poli V, et al. 2021. iScience. 24:103256. PubMed
  53. Matsumoto R, et al. 2021. Front Pharmacol. 12:715752. PubMed
  54. Alam J, et al. 2022. Mucosal Immunol. 15:620. PubMed
  55. Devalaraja S, et al. 2020. Cell. 1098:180. PubMed
  56. Upadhyaya P, et al. 2021. J Immunother Cancer. 9:00. PubMed
  57. Hiraishi Y, et al. 2018. Sci Rep. 8:18052. PubMed
  58. Wang L, et al. 2022. Cancer Res Commun. 2:518. PubMed
  59. Starkl P, et al. 2020. Immunity. 53(4):793-804.e9. PubMed
  60. Wang Y, et al. 2021. Cancer Cell. 39:1375. PubMed
  61. Antonia O Cuff et al. 2017. Wellcome open research. 2:39 . PubMed
  62. Di Gioia M, et al. 2020. Nat Immunol. 21:42. PubMed
  63. Somerville TD, et al. 2020. eLife. 9:e53381.. PubMed
  64. Lees JG, et al. 2020. PLoS One. 15:e0238164. PubMed
  65. Sun Q, et al. 2022. Cell Death Dis. 13:724. PubMed
  66. Yoshihara E, et al. 2020. Nature. 606:586. PubMed
  67. Huang X, et al. 2020. Cell Host Microbe. 29(2):210-221.e6. PubMed
  68. LaMarche NM, et al. 2020. Cell Metabolism. 32(2):243-258.e6. PubMed
  69. Cuff AO, et al. 2020. Frontiers in Immunology. 1.930555556. PubMed
  70. Thanabalasuriar A et al. 2019. Cell Host Microbe. 25(4):526-536 . PubMed
  71. Yu M, et al. 2021. J Clin Invest. 131:. PubMed
  72. Ma M, et al. 2021. Front Immunol. 12:718779. PubMed
  73. Xu Y, et al. 2021. Stem Cell Res Ther. 12:112. PubMed
  74. Dikiy S, et al. 2021. Immunity. 54(5):931-946.e11. PubMed
  75. Devalaraja S, et al. 2020. STAR Protoc. 1:100188. PubMed
  76. Pandey V, et al. 2021. eLife. 0.416666666666667. PubMed
  77. Taguchi K, et al. 2015. J Urol. . PubMed
  78. Duc D et al. 2019. Cell Rep. 29(2):378-390 . PubMed
  79. Linde N, et al. 2018. Nat Commun. 9:21. PubMed
  80. Wang H, et al. 2021. Malar J. 20:249. PubMed
  81. Taguchi K, et al. 2014. J Am Soc Nephrol. 25:1680. PubMed
  82. Tyagi AM, et al. 2021. eLife. 10:00. PubMed
  83. Neupane AS, et al. 2020. Cell. 183(1):110-125.e11. PubMed
  84. Thiriot A et al. 2017. BMC biology. 15(1):45 . PubMed
  85. Knolle MD et al. 2018. Frontiers in immunology. 1.925 . PubMed
  86. Linehan JL et al. 2018. Cell. 172(4):784-796 . PubMed
  87. Kooreman NG et al. 2018. Cell stem cell. 22(4):501-513 . PubMed
  88. Bonnardel J, et al. 2019. Immunity. 51:638. PubMed
  89. Leylek R, et al. 2019. Cell Rep. 29:3736. PubMed
  90. Yang P, et al. 2022. Nat Commun. 13:5782. PubMed
  91. Weaver JD, et al. 2022. Oncoimmunology. 11:2141007. PubMed
  92. Brigas HC, et al. 2021. Cell Reports. 36(9):109574. PubMed
  93. Dang MT, et al. 2021. Cell Reports. 34(13):108917. PubMed
  94. Nagai M, et al. 2020. Cell. 178(5):1072-1087.e14.. PubMed
  95. Silver J, et al. 2020. Methods Mol Biol. 2121:115. PubMed
  96. Zhang Y, et al. 2021. J Immunol Res. 2021:5599439. PubMed
  97. Reinfeld BI, et al. 2021. Nature. 593:282. PubMed
  98. Panea C, et al. 2021. Commun Biol. 4:913. PubMed
  99. Lima-Junior DS, et al. 2021. Cell. . PubMed
  100. Jacobson A et al. 2018. Cell host & microbe. 24(2):296-307 . PubMed
  101. Casulli J, et al. 2019. Nat Commun. 10:2121. PubMed
  102. Cheng Y, et al. 2019. Clin Cancer Res. 25:2621. PubMed
  103. Alam J, et al. 2021. Front Immunol. 12:701415. PubMed
  104. Jorapur A, et al. 2022. PLoS Pathog. 18:e1010200. PubMed
  105. Kalavska K, et al. 2021. Int J Mol Sci. 22:. PubMed
  106. Frenis K, et al. 2021. Basic Res Cardiol. 31:116. PubMed
  107. Dewi IMW, et al. 2021. Cell Reports Medicine. 2(5):100289. PubMed
  108. Walsh SM, et al. 2021. eLife. 10:00. PubMed
  109. LM S, et al. 2016. Cell Rep. 16(12): 3286-96. PubMed
  110. Guilliams M, et al. 2022. Cell. 185:379. PubMed
  111. Stacy A, et al. 2021. Cell. 184(3):615-627.e17. PubMed
  112. Alam Z, et al. 2020. Cell Rep. 107825:31. PubMed
  113. Xiao Y, et al. 2018. Int Immunol. 30:457. PubMed
  114. Ayari A, et al. 2020. Commun Biol. 3:237. PubMed
  115. Dang MT, et al. 2021. STAR Protoc. 2:100957. PubMed
  116. Espinal A, et al. 2022. Int J Mol Sci. 23:. PubMed
  117. Louka E, et al. 2021. Journal of Experimental Medicine. 218(2):. PubMed
  118. Holm J, et al. 2015. PLoS One. 10:125495. PubMed
  119. Jordan S, et al. 2020. Cell. 178(5):1102-1114.e17.. PubMed
  120. Gladow N, et al. 2020. PLoS One. 15:e0227734. PubMed
  121. Kalavska K, et al. 2022. Front Oncol. 12:858797. PubMed
  122. Zhang XW, et al. 2021. Oncoimmunology. 10:1920739. PubMed
  123. Zeis P, et al. 2020. Immunity. 53:775. PubMed
  124. Calderon B, et al. 2015. J Exp Med. 212: 1497-1512. PubMed
  125. Tian Y, et al. 2020. JCI Insight. 5:00. PubMed
  126. Jiang L, et al. 2020. Cell. 183(5):1219-1233.e18. PubMed
  127. Hoffmann J, et al. 2021. Nat Commun. 12:3964. PubMed
  128. Carlson PM, et al. 2021. J Immunol. 207:720. PubMed
  129. Seki N, et al. 2022. iScience. 25:104838. PubMed
  130. Chen H, et al. 2022. Mol Ther Methods Clin Dev. 27:431. PubMed
  131. Montalban-Arques A, et al. 2021. Cell Host Microbe. :. PubMed
  132. Asadi Shahmirzadi A, et al. 2020. Cell Metabolism. 32(3):447-456.e6. PubMed
  133. Mairhofer D, et al. 2015. J Invest Dermatol. 135: 2785-93. PubMed
  134. Silva DA, et al. 2019. Nature. 565:186. PubMed
  135. Xu JL, et al. 2022. Front Pharmacol. 13:911663. PubMed
  136. Hering L, et al. 2020. Front Immunol. 1.747222222. PubMed
  137. Halim TYF et al. 2018. Immunity. 48(6):1195-1207 . PubMed
  138. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  139. Sugita Y, et al. 2021. Oncol Rep. 45:. PubMed
  140. Zamarin D, et al. 2020. Clin Cancer Res. 26:4531. PubMed
  141. Domanska D, et al. 2022. J Exp Med. 219:. PubMed
  142. Liu J, et al. 2022. Nat Commun. 13:4308. PubMed
  143. Aulova KS, et al. 2022. Molecules. 27:. PubMed
  144. Xia L, et al. 2021. Cell Chemical Biology. 28(5):610-624.e5. PubMed
  145. Wan X, Thomas J, Unanue E 2016. J Exp Med. 213: 967 - 978. PubMed
  146. Ramanan D, et al. 2020. Cell. 181(6):1276-1290. PubMed
  147. Li X, et al. 2022. Oncoimmunology. 11:2118210. PubMed
  148. Smith LK, et al. 2021. Elife. 10:. PubMed
  149. Catrysse L, et al. 2021. Cell Rep. 36:109748. PubMed
  150. Wang X, et al. 2021. Theranostics. 11:209. PubMed
  151. Tran S, et al. 2020. Immunity. 53(3):627-640.e5. PubMed
  152. Wang X, et al. 2021. Immunity. 54(6):1123-1136.e8. PubMed
  153. Wunderlich CM, et al. 2018. Nat Commun. 9:1646. PubMed
  154. Li Z et al. 2018. Immunity. 49(4):640-653 . PubMed
  155. Tripathi A, et al. 2021. Mol Psychiatry. 26:3043. PubMed
  156. Jiang M, et al. 2021. Front Pharmacol. 12:657486. PubMed
  157. Dourcy M, et al. 2020. Mucosal Immunol. 13:799. PubMed
  158. Sfakianos JP, et al. 2020. Nat Commun. 2.222222222. PubMed
  159. Deniset JF et al. 2019. Immunity. 51(1):131-140 . PubMed
  160. Weinstock A, et al. 2019. Immunometabolism. 1. PubMed
  161. Figueiredo CA, et al. 2022. J Neuroinflammation. 19:17. PubMed
  162. Li X, et al. 2021. Front Cell Dev Biol. 9:647713. PubMed
RRID
AB_2561392 (BioLegend Cat. No. 103137)
AB_2561392 (BioLegend Cat. No. 103138)

Antigen Details

Structure
Protein tyrosine phosphatase (PTP) family, 180-240 kD
Distribution

All hematopoietic cells except mature erythrocytes and platelets

Function
Phosphatase, T and B cell activation
Ligand/Receptor
Galectin-1, CD2, CD3, CD4, TCR, CD22, Thy-1
Cell Type
B cells, Dendritic cells, Mesenchymal Stem Cells, Tregs
Biology Area
Cell Biology, Immunology, Inhibitory Molecules, Innate Immunity, Neuroscience, Neuroscience Cell Markers, Stem Cells
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Trowbridge IS, et al. 1993. Annu. Rev. Immunol. 12:85.
3. Kishihara K, et al. 1993. Cell 74:143.
4. Pulido R, et al. 1988. J. Immunol. 140:3851.

Gene ID
19264 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
CD45
Specificity Alt (DOES NOT SHOW ON TDS):
CD45
App Abbreviation (DOES NOT SHOW ON TDS):
FC
UniProt
View information about CD45 on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD45 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD45 30-F11 FC
Biotin anti-mouse CD45 30-F11 FC
FITC anti-mouse CD45 30-F11 FC
PE anti-mouse CD45 30-F11 FC
PE/Cyanine5 anti-mouse CD45 30-F11 FC
Purified anti-mouse CD45 30-F11 FC,IHC-F,CyTOF®,IP,CMCD,IHC,WB
PE/Cyanine7 anti-mouse CD45 30-F11 FC
APC/Cyanine7 anti-mouse CD45 30-F11 FC
Alexa Fluor® 488 anti-mouse CD45 30-F11 FC,SB
Alexa Fluor® 647 anti-mouse CD45 30-F11 FC,ICC,IHC,3D IHC,SB
Pacific Blue™ anti-mouse CD45 30-F11 FC
Alexa Fluor® 700 anti-mouse CD45 30-F11 FC,SB
PerCP/Cyanine5.5 anti-mouse CD45 30-F11 FC
PerCP anti-mouse CD45 30-F11 FC
Alexa Fluor® 594 anti-mouse CD45 30-F11 IHC-F,FC,3D IHC
Brilliant Violet 421™ anti-mouse CD45 30-F11 FC,SB
Brilliant Violet 570™ anti-mouse CD45 30-F11 FC
Brilliant Violet 510™ anti-mouse CD45 30-F11 FC
Brilliant Violet 605™ anti-mouse CD45 30-F11 FC
Purified anti-mouse CD45 (Maxpar® Ready) 30-F11 FC,CyTOF®
PE/Dazzle™ 594 anti-mouse CD45 30-F11 FC
Brilliant Violet 711™ anti-mouse CD45 30-F11 FC
Brilliant Violet 785™ anti-mouse CD45 30-F11 FC
Brilliant Violet 650™ anti-mouse CD45 30-F11 FC
APC/Fire™ 750 anti-mouse CD45 30-F11 FC
Brilliant Violet 750™ anti-mouse CD45 30-F11 FC
TotalSeq™-A0096 anti-mouse CD45 30-F11 PG
TotalSeq™-B0096 anti-mouse CD45 30-F11 PG
Ultra-LEAF™ Purified anti-mouse CD45 30-F11 FC,CyTOF®,IP,CMCD,IHC,WB
Spark Blue™ 550 anti-mouse CD45 30-F11 FC
Spark NIR™ 685 anti-mouse CD45 30-F11 FC
TotalSeq™-C0096 anti-mouse CD45 30-F11 PG
Spark YG™ 570 anti-mouse CD45 30-F11 IHC-F
PE/Fire™ 640 anti-mouse CD45 30-F11 FC
APC/Fire™ 810 anti-mouse CD45 30-F11 FC
PE/Fire™ 700 anti-mouse CD45 30-F11 FC
Spark Violet™ 538 anti-mouse CD45 30-F11 FC
Spark YG™ 593 anti-mouse CD45 30-F11 FC
Spark Blue™ 574 anti-mouse CD45 Antibody 30-F11 FC
Spark Blue™ 515 anti-mouse CD45 30-F11 FC
Spark UV™ 387 anti-mouse CD45 30-F11 FC
PE/Fire™ 810 anti-mouse CD45 30-F11 FC
Spark Red™ 718 anti-mouse CD45 (Flexi-Fluor™) 30-F11 FC
Spark PLUS UV395™ anti-mouse CD45 30-F11 FC
Go To Top Version: 2    Revision Date: 05.14.2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account